TERN Stock Risk & Deep Value Analysis
Terns Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About TERN Stock
We analyzed Terns Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TERN through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is TERN Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
High
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for TERN?
- ⚠
Negative or inconclusive clinical trial results for TERN-701 Phase 3
- ⚠
Inability to secure a strategic partnership on favorable terms
- ⚠
Significant competitor breakthrough or regulatory approval
- ⚠
Further equity dilution without commensurate pipeline progress
Unlock TERN Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Terns Pharmaceuticals Inc (TERN) Do?
Market Cap
$4.51B
Sector
Healthcare
Industry
Biotechnology
Employees
59
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Visit Terns Pharmaceuticals Inc WebsiteIs TERN Stock Undervalued?
Unlock the full AI analysis for TERN
Get the complete DVR score, risk analysis, and more
Does TERN Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat is primarily built on the patent protection and clinical differentiation of TERN-701. Its durability hinges on successful Phase 3 trials confirming a superior safety/efficacy profile compared to existing BTK inhibitors, leading to regulatory approval and subsequent market adoption. If approved, the IP would provide a competitive barrier for a significant period.
Moat Erosion Risks
- •Clinical trial failure or inconclusive results for TERN-701
- •Emergence of superior or equally differentiated competitor compounds
- •Patent challenges or loss of exclusivity sooner than expected
- •Safety concerns arising in larger patient populations post-approval
TERN Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive TERN Stock Higher?
Near-Term (0-6 months)
- •TERN-701 Phase 3 trial initiation announcement (expected H1 2026)
- •Strategic partnership announcement for TERN-701 development/commercialization (expected H1-H2 2026)
- •Q4 2025/Full Year 2025 Earnings Report (Expected early-to-mid May 2026)
Medium-Term (6-18 months)
- •Initial readouts or interim analysis from early Phase 3 cohorts (if applicable, 6-12 months post-initiation)
- •Update on other pipeline assets (e.g., TERN-501) and their strategic path
- •Expansion of TERN-701 into additional B-cell malignancy indications
Long-Term (18+ months)
- •Pivotal Phase 3 data readout for TERN-701
- •Regulatory submission and potential approval for TERN-701
- •Commercial launch and market penetration of TERN-701
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for TERN?
- ✓
Announcement of TERN-701 Phase 3 trial design and initiation timeline
- ✓
Details of any strategic partnership (financial terms, development responsibilities, indications)
- ✓
Updates on cash runway and burn rate from quarterly earnings
- ✓
Competitor clinical trial readouts in the BTK inhibitor space
Bull Case Analysis
See what could go right with Premium
Compare TERN to Similar Stocks
See how Terns Pharmaceuticals Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TERN (Terns Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
